CardioPharma

Executive Summary

CardioPharma is a privately held biopharmaceutical company based in San Diego, focused on developing and commercializing fixed-dose combination (FDC) polypill therapies for cardiovascular disease (CVD). Its lead candidate, CardiaPill®, combines a statin, an ACE inhibitor, and an anti-platelet agent into a single once-daily pill, aiming to simplify treatment regimens, improve patient adherence, and reduce healthcare costs. Founded in 2003, the company operates in the drug delivery space but has not disclosed funding or valuation. CardioPharma's strategy targets the large and growing CVD market, where polypills could address poor adherence to multi-drug regimens. However, the company faces competition from established polypill products and must navigate regulatory hurdles to bring CardiaPill® to market. Given its limited public pipeline and financial transparency, CardioPharma's near-term prospects hinge on clinical and regulatory progress.

Upcoming Catalysts (preview)

• Q2 2026FDA Approval Decision for CardiaPill®40% success
• Q4 2026Commercial Partnership Announcement60% success
• Q1 2027Phase 3 Clinical Trial Results50% success